Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

on in managing their cholesterol levels.

"There is a lot of interest in PCSK9 as an exciting new target for the treatment of high cholesterol and having demonstrated that SPC5001 effectively lowers LDL or the 'bad' cholesterol in preclinical studies, we are quickly moving forward with plans to advance SPC5001 into clinical studies as a potential new treatment to help patients better manage the risks of cardiovascular diseases," said Henrik Orum, PhD, Vice President and Chief Scientific Officer of Santaris Pharma A/S. "SPC5001 is a testament to the efficiency of our LNA Drug Platform and Drug Discovery Engine as we discovered, optimized and advanced SPC5001 into preclinical development in just 18 months."

The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the Company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates for a range of diseases including metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

"In addition to advancing SPC5001 into drug development for the treatment of high cholesterol, we remain on track to begin Phase 2 clinical trials of miravirsen (SPC3649) in patients with Hepatitis C in the second half of this year," said Soren Tulstrup, President and Chief Executive Officer, Santaris Pharma A/S. "In our internal programs and partnered programs, the versatility and broad utility of Santaris Pharma A/S LNA Drug Platform and Drug Discovery Engine continues to be critical in developing effective RNA-targeted therapies with high affinity, target specificity and remarkable potency for a range of diseases."

SPC5001 adds to the portfolio of Santaris Pharma A/S drugs in development, including its most advanced c
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Eckert & ... Mass Spectrometry (AMS) services to the pharmaceutical and biotech ... joined the company in the position of Director of ... of broad and valuable experience in drug metabolism and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 GEA Niro ... table top laboratory homogenizer, the PandaPLUS 2000, which is ... nanoemulsions , and cell disruption . This compact ... products, fruit juices, liquid food, food additives and ingredients ...
(Date:1/22/2015)... The laboratory information management systems market is ... of technological advancements due to factors such as rising ... integrate healthcare systems, and increasing government support for adoption ... Key players in the market focus on technological advancements ...
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... March 13 Innocoll, Inc., a,privately-held biopharmaceutical ... of planned phase 2 clinical trials sponsored ... to investigate CollaRx(R),BUPIVACAINE SURGICAL IMPLANT for the ... Innocoll,s BUPIVACAINE SURGICAL IMPLANT is a biodegradable ...
... scientists worldwide gain new insight ... funding support for human brain, spinal cord and developing ... brain projects, ... it is undertaking three major projects designed to,accelerate brain, and spinal cord research, ...
... 93.3%; Full Year Net Income up 283.0%, SHANGHAI, ... WX ), the leading global pharmaceutical,biotechnology and medical ... its unaudited financial results for the,fourth quarter and full ... 2007 Highlights:, Compared to the fourth quarter 2006 ...
Cached Biology Technology:Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 2Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 3Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 4Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 12
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... (WSU) Laboratory for Atmospheric Research is leading a nationwide ... the distribution of natural gas. Beginning this month, ... Lamb will quantify methane emissions throughout local gas systems ... data to estimate a national methane emissions rate for ...
... the University of Michigan have identified a new potential ... alternative or complementary therapy to statins. Scientists ... Sciences Institute inhibited the action of a gene responsible ... of the liver to remove cholesterol from the blood ...
... animals are frequently observed scavenging on other animals whether it ... or a buzzard swooping down on a dead animal. However, ... difficult, and often overlooked in marine food web studies. , ... titled, " White sharks ( Carcharodon carcharias ) scavenging on ...
Cached Biology News:Methane emissions from natural gas local distribution focus of new study 2Methane emissions from natural gas local distribution focus of new study 3U-M researchers find new way to clear cholesterol from the blood 2Great white sharks 2
BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
...
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
... Nikon's NIS-Elements revolutionizes imaging software for ... intelligence to microscopes, cameras, components and ... and achiving tools. Its intuitive interface ... acquisition times while providing powerful features ...
Biology Products: